CD8A and neoplasm: In these tumour sections, the number of CD8+ T cells in the control, pHIFU, ICI and pHIFU + ICI groups (expressed as a percentage of the number of tumour cells) were 2.3 ± 1.6%, 4.7 ± 3.0%, 2.3 ± 1.9% and 5.8 ± 4.0%, respectively, 12 days after treatment (figure 4b).